Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-06 pm EDT 		5-day change 1st Jan Change
13.39 USD +0.68% Intraday chart for Evolus, Inc. +14.35% +27.16%
Apr. 26 AbbVie raises annual profit forecast on strong Skyrizi sales RE
Apr. 17 Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie raises annual profit forecast on strong Skyrizi sales
RE
Evolus to Report First Quarter Financial Results on May 7, 2024
BU
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
BU
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau
CI
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus, Inc. Announces Board Changes
CI
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing
MT
Transcript : Evolus, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Evolus Prices $50 Million Share Offering
MT
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating
MT
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results, Reaffirms 2024 Guidance
AQ
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours
MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Evolus, Inc., Q4 2023 Earnings Call, Mar 07, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW